The MyoKardia Gang Just Pulled Off a $400M Comeback

Three Drugs, One Obsession

Kardigan isn't dabbling in cardiology. It's all-in, with three late-stage clinical programs running simultaneously.

Danicamtiv is the headliner. It's a direct myosin activator (translation: it helps the heart muscle contract more effectively) being tested in a Phase 2b/3 trial called KINSHIP-DCM. The target is genetic dilated cardiomyopathy, a condition where the heart's pumping chamber stretches and weakens. There's no approved drug specifically designed for this patient population, which makes danicamtiv a potential first-in-class therapy.

Ataciguat goes after a completely different problem: calcific aortic valve stenosis, where calcium deposits stiffen the heart's aortic valve. Right now, patients basically wait until the valve gets bad enough to replace surgically. Ataciguat, an oral pill taken once daily, aims to slow that progression. It's in a Phase 2b trial called KATALYST-AV.

Tonlamarsen rounds out the trio. It's a once-monthly injection (an antisense oligonucleotide, or ASO) that targets the liver to reduce a protein called angiotensinogen, which plays a key role in blood pressure regulation. The Phase 2b trial, KARDINAL-ASH, is focused on acute severe hypertension.

All three programs are expected to deliver data readouts in the first half of 2027. That's a lot of catalysts packed into one stretch, which partly explains why investors were willing to pay up.

The IPO Market Is Open (If You Have the Right Résumé)

Kardigan's debut was big, but it wasn't the biggest biotech IPO this year. That honor belongs to Parabilis Medicines at $670 million, followed by Kailera Therapeutics at $625 million. Kardigan's $400 million ties it with Generate Biomedicines for what appears to be the third-largest slot.

Still, context matters. The biotech IPO market was practically comatose through most of 2024 and 2025. Only nine biopharma companies went public through Q4 2025, raising a combined $1.6 billion; that was the least active stretch in over a decade. The fact that four drug startups have now raised at least $400 million each in 2026 IPOs tells you something has shifted.

But this isn't 2021 all over again. Analysts have been careful to distinguish between "the window is open" and "the party is back." IPOX's Lukas Muehlbauer noted that the current market is rewarding companies with mature programs and visible milestones, not handing out blank checks to anyone with a preclinical slide deck. Capital is flowing selectively, concentrating in fewer, more de-risked companies.

Cardiovascular biotech, in particular, is having a moment. Cardio venture funding hit $500 million across 16 deals in Q1 2025 alone, nearly matching the sector's entire 2024 total of $542 million. Investor interest spans heart failure, hypertension, rhythm disorders, and atherosclerosis. Kardigan, with its diversified cardiac pipeline and pedigreed team, checked almost every box the market was looking for.

The Fine Print Nobody Wants to Talk About

For all the enthusiasm, there's a notable caveat buried in the filings. Prior to its IPO, Kardigan had acknowledged in its filings that it wouldn't have enough cash reserves to fund operations for at least 12 months without additional capital. Three simultaneous late-stage trials are expensive, and the $400 million (or even $460 million with the greenshoe) may not stretch as far as investors hope.

Future capital raises could dilute existing shareholders, and the timing of those raises will depend heavily on how the clinical data readouts land. If the trials deliver, Kardigan will be raising from a position of strength. If any of them stumble, the math gets trickier fast.

The Bottom Line

Kardigan's IPO is a Rorschach test for where biotech stands in late 2026. Optimists see a company built by proven operators, armed with differentiated science, raising at the top of its range in a recovering market. Skeptics see a pre-revenue company burning through cash on three concurrent trials, backed by a management halo that may or may not translate to clinical success.

Both readings are probably correct. The MyoKardia pedigree bought Kardigan a premium valuation and a massive war chest. Now the team has to prove the science works, again, in three different indications at the same time. The data readouts expected in the first half of next year will determine whether KARD becomes a cardiology powerhouse or an expensive lesson in biotech nostalgia.

For now, Wall Street is betting on the reunion tour. The opening-day pop suggests the crowd liked the first song.

The Cancer Therapy That Killed Three People Who Didn't Have Cancer

Three patients with autoimmune diseases died in Novartis CAR-T trials, forcing the company to pause eight studies and the entire field to confront an uncomfortable question: can cancer's most powerful therapy ever be safe enough for diseases that aren't trying to kill you?